Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vedolizumab SC Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961295
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

NCT02611817
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab SC 108 mg, Placebo, Vedolizumab IV 300 mg
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Phoenix, Arizona • Hamden, Connecticut • Middletown, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis

NCT02611830
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab 300 mg IV, Placebo IV, Vedolizumab 108 mg SC, Placebo SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
28
States / cities
Little Rock, Arkansas • Wheat Ridge, Colorado • Middletown, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 2, 2026, 1:43 AM EDT
Recruiting Phase 3 Interventional

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

NCT06100289
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab IV, Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 2, 2026, 1:43 AM EDT
Recruiting Phase 4 Interventional

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

NCT06045754
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab, Adalimumab, Ustekinumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
41
States / cities
Dothan, Alabama • Sun City, Arizona • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 1:43 AM EDT
Recruiting Phase 3 Interventional

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT06405087
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab SC, No Intervention
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
14
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants

NCT03948581
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 2, 2026, 1:43 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Risankizumab, Vedolizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
74
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 65 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 2, 2026, 1:43 AM EDT
Active, not recruiting No phase listed Observational

Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

NCT07123350
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD), Ulcerative Colitis (UC)
Interventions
Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 4 Interventional Results available

Triple Combination Therapy in High Risk Crohn's Disease (CD)

NCT02764762
View directory record Official record
Conditions
Crohn Disease
Interventions
Vedolizumab, Adalimumab, Methotrexate
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
27
States / cities
Dothan, Alabama • Clearwater, Florida • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961308
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

NCT02497469
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab, Adalimumab placebo, Adalimumab, Vedolizumab placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants

NCT03949621
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 2, 2026, 1:43 AM EDT
Completed Phase 3 Interventional Results available

A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

NCT02620046
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn's Disease
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
47
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Wheat Ridge, Colorado + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 2, 2026, 1:43 AM EDT
Recruiting Phase 4 Interventional

A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

NCT06581328
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab IV, Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 2, 2026, 1:43 AM EDT